PLoS Neglected Tropical Diseases (Aug 2021)

Passive surveillance of human African trypanosomiasis in Côte d'Ivoire: Understanding prevalence, clinical symptoms and signs, and diagnostic test characteristics.

  • Minayégninrin Koné,
  • Dramane Kaba,
  • Jacques Kaboré,
  • Lian Francesca Thomas,
  • Laura Cristina Falzon,
  • Mathurin Koffi,
  • Cyrille Mambo Kouamé,
  • Bernardin Ahouty,
  • Charlie Franck Alfred Compaoré,
  • Emmanuel Kouassi N'Gouan,
  • Philippe Solano,
  • Eric Fèvre,
  • Philippe Büscher,
  • Veerle Lejon,
  • Vincent Jamonneau

DOI
https://doi.org/10.1371/journal.pntd.0009656
Journal volume & issue
Vol. 15, no. 8
p. e0009656

Abstract

Read online

BackgroundLittle is known about the diagnostic performance of rapid diagnostic tests (RDTs) for passive screening of human African trypanosomiasis (HAT) in Côte d'Ivoire. We determined HAT prevalence among clinical suspects, identified clinical symptoms and signs associated with HAT RDT positivity, and assessed the diagnostic tests' specificity, positive predictive value and agreement.MethodsClinical suspects were screened with SD Bioline HAT, HAT Sero-K-Set and rHAT Sero-Strip. Seropositives were parasitologically examined, and their dried blood spots tested in trypanolysis, ELISA/Tbg, m18S-qPCR and LAMP. The HAT prevalence in the study population was calculated based on RDT positivity followed by parasitological confirmation. The association between clinical symptoms and signs and RDT positivity was determined using multivariable logistic regression. The tests' Positive Predictive Value (PPV), specificity and agreement were determined.ResultsOver 29 months, 3433 clinical suspects were tested. The RDT positivity rate was 2.83%, HAT prevalence 0.06%. Individuals with sleep disturbances (pConclusionIdentification of five key clinical symptoms and signs may simplify referral for HAT RDT screening. The results confirm the appropriateness of the diagnostic algorithm presently applied, with screening by SD Bioline HAT or HAT Sero-K-Set, supplemented with trypanolysis. ELISA/Tbg could replace trypanolysis and is simpler to perform.Trial registrationClinicalTrials.gov NCT03356665.